Inhibition of bladder tumor growth by chitooligosaccharides in an experimental carcinogenesis model

Marine Drugs

Volumn 10, Issue 12, 2012, Pages 2661-2675

  Fernandes, João C ^a,b,c   Sereno, José ^b   Garrido, Patricia ^b   Parada, Belmiro ^d   Cunha, Maria F X ^d   Reis, Flávio ^b   Pintado, Manuela E ^c   Santos Silva, Alice ^a,e  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSIDADE CATÓLICA PORTUGUESA   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

Bladder cancer; Chemoprevention; Chitooligosaccharides; Chitosans

Indexed keywords

ANTINEOPLASTIC AGENT; CHITOSE OLIGOSACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BLADDER CANCER; BLOOD ANALYSIS; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LOW DRUG DOSE; MALE; MOLECULAR WEIGHT; NONHUMAN; ORANGE JUICE; RAT; TUMOR GROWTH;

RATTUS;

EID: 84871733767     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md10122661     Document Type: Article

References (46)

1. Lin, C.W.; Chen, L.J.; Lee, P.L.; Lee, C.I.; Lin, C.J.; Chiu, J.J. The inhibition of TNF-α-induced E-selectin expression in endothelial cells via the JNK/NF-κB pathways by highly N-acetylated chitooligosaccharides. Biomaterials 2007, 28, 1355-1366.
2. Vernazza, C.L.; Gibson, G.R.; Rastall, R.A. In vitro fermentation of chitosan derivatives by mixed cultures of human faecal bacteria. Carbohydr. Polym. 2005, 60, 539-545. (Pubitemid 40744096)
3. Rasmussen, R.S.; Morrissey, M.T. Marine Nutraceuticals and Functional Foods; Shahidi, F., Barrow, C., Eds.; CRC Press: New York, NY, USA, 2008; pp. 155-182.
4. Roller, S.; Covill, N. The antifungal properties of chitosan in laboratory media and apple juice. Int. J. Food Microbiol. 1999, 47, 66-77.
5. Vårum, K.M.; Ottøy, M.H.; Smidsrød, O. Water-solubility of partially N-acetylated chotosans as a function of pH, effect of chemical composition and depolymerisation. Carbohydr. Polym. 1994, 25, 65-70.
6. Kim, S.K.; Rajapakse, N. Enzymatic production and biological activities of chitosan oligosaccharides (COS): A review. Carbohydr. Polym. 2005, 62, 357-368. (Pubitemid 41745217)
7. Chae, S.Y.; Jang, M.K.; Nah, J.W. Influence of molecular weight on oral absorption of water soluble chitosans. J. Control Release 2005, 102, 383-394.
8. Reddy, B.S.; Hamid, R.; Rao, C.V. Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition. Carcinogenesis 1997, 18, 1371-1374. (Pubitemid 28134712)
9. Wijnands, M.V.W.; Appel, M.J.; Hollanders, V.M.H.; Woutersen, R.A.A. Comparison of the effects of dietary cellulose and fermentable galacto-oligosaccharide, in a rat model of colorectal carcinogenesis, fermentable fibre confers greater protection than non-fermentable fibre in both high and low fat backgrounds. Carcinogenesis 1999, 20, 651-656.
10. Wijnands, M.V.W.; Schoterman, H.C.; Bruijntjes, J.P.; Hollanders, V.M.H.; Wouterse, R.A. Effect of dietary galacto-oligosaccharides on azoxymethane-induced aberrant crypt foci and colorectal cancer in Fischer 344 rats. Carcinogenesis 2001, 22, 127-132.
11. Maeda, Y.; Kimura, Y. Antitumor effects of various low molecular-weight chitosans are due to increased natural killer activity of intestinal intraepithelial lymphocytes in sarcoma 180-bearing mice. Nutr. Cancer 2004, 134, 945-950. (Pubitemid 38456269)
12. Grasso, M. Bladder cancer: A major public health issue. Eur. Urol. Suppl. 2008, 7, 510-515.
13. Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M.; Boyle, P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 2007, 18, 581-592. (Pubitemid 46359643)
14. Pisani, P.; Bray, F.; Parkin, D.M. Estimates of world-wide prevalence of cancer for 25 sites in the adult prevalence. Int. J. Cancer 2002, 97, 72-81.
15. Sylvester, R.J.; van der Meijden, A.P.; Oosterlinck, W.; Witjes, J.A.; Bouffioux, C.; Denis, L.; Newling, D.W.; Kurth, K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables, a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 2006, 49, 466-477.
16. Kirkali, Z.; Chan, T.; Manoharan, M.; Algaba, F.; Busch, C.; Cheng, L.; Kiemeney, L.; Kriegmair, M.; Montironi, R.; Murphy, W.M.; et al. Bladder cancer: Epidemiology, staging, grading and diagnosis. Urology 2005, 66, 4-34.
17. Sangar, V.K.; Ragavan, N.; Matanheleia, S.S.; Watson, M.W.; Blades, R.A. The economic consequences of prostate and bladder cancer in UK. BJU Int. 2005, 95, 59-63. (Pubitemid 350020870)
18. Malkowicz, S.B.; van Poppel, H.; Mickisch, G.; Pansadoro, V.; Thüroff, J.; Soloway, M.S.; Chang, S.; Benson, M.; Fukui, I. Muscle-invasive urothelial carcinoma of the bladder. Urology 2007, 69, 3-16. (Pubitemid 46186483)
19. Evans, C.; Debruyne, F.; Payne, H.; Solsona, E.; Teillac, P.; Tubaro, A. Bladder cancer, management and future directions. Eur. Urol. Suppl. 2007, 6, 365-373. (Pubitemid 46149478)
20. Fukushima, S.; Hirose, M.; Tsuda, H.; Shirai, T.; Hirao, K. Histological classification of urinary bladder cancers in rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Gann 1976, 67, 81-90.
21. Montironi, R.; Mazzucchelli, R. Preneoplastic Lesions and Conditions of the urinary bladder. EAU Update Ser. 1976, 1, 53-63.
22. Sauter, G.; Algaba, F.; Amin, M.; Busch, C.; Cheville, J.; Gasser, T.; Grignon, D.J.; Hofstadter, F.; Lopez-Beltran, A.; Epstein, J.I. WHO Classification of Tumors of the Urinary System and Male Genital Organs; Eble, J.N., Sauter, G., Epstein, J.L., Sesterhenn, I., Eds.; IARCC Press: Lyon, France, 2004; pp. 29-34.
23. Gofrit, O.N.; Birman, T.; Ayesh, S.; Ohana, P.; Hochberg, A. Chemically induced bladder cancer-A sonographic and norphologic description. Urology 2006, 68, 231-235. (Pubitemid 44037755)
24. Hameed, D.A.; el-Metwally, T.H. The effectiveness of retinoic acid treatment in bladder cancer, impact on recurrence, survival and TGF-alpha and VEGF as end-point biomarkers. Cancer Biol. Ther. 2008, 7, 92-100.
25. Leppert, J.T.; Shvarts, O.; Kawaoka, K.; Lieberman, R.; Belldegrun, A.S.; Pantuck, A.J. Prevention of bladder cancer: A review. Eur. Urol . 2006, 49, 226-234. (Pubitemid 43197858)
26. Parada, B.; Sereno, J.; Reis, F.; Teixeira-Lemos, E.; Garrido, P.; Pinto, A.F.; Cunha, M.F.; Pinto, R.; Mota, A.; Figueiredo, A.; Teixeira, F. Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biol. Ther. 2009, 8, 1615-1622.
27. Hattori, K.; Iida, K.; Joraku, A.; Tsukamoto, S.; Akaza, H.; Oyasu, R. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int. 2006, 97, 640-643.
28. Nam, K.S.; Shon, Y.H. Suppression of metastasis of human breast cancer cells by chitosan oligosaccharides. J. Microbiol. Biotechnol. 2009, 19, 629-633.
29. Suzuki, K.; Mikami, T.; Okawa, Y.; Tokoro, A.; Suzuki, S.; Suzuki, M. Antitumor effect of hexa-N-acetylchitohexaose and chitohexaose. Carbohydr. Res . 1986, 151, 403-408.
30. Tokoro, A.; Tatewaki, N.; Suzuki, K.; Mikami, T.; Suzuki, S.; Suzuki, M. Growth-inhibitory effect of hexa-N-acetylchitohexaose and chitohexaose against Meth-A solid tumor. Chem. Pharm. Bull . 1988, 36, 784-790. (Pubitemid 18072083)
31. Wang, J.; Chen, Y.; Ding, Y.; Shi, G.; Wan, C. Research of the degradation products of chitosan's angiogenic function. Appl. Surf. Sci . 2008, 255, 260-262.
32. Kam, P.C.; See, A.U. Cyclo-oxygenase isoenzymes, physiological and pharmacological role. Anaesthesia 2000, 55, 442-449. (Pubitemid 30301443)
33. Harris, R.E. Cyclooxygenase-2 (COX-2) and the inflammogenesis of cancer. Subcell. Biochem. 2007, 42, 93-126.
34. DeGortari, A.E.; Han, C.; Glickman, L.T. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother. Pharmacol. 2000, 46, 221-226.
35. Grubbs, C.J.; Lubet, R.A.; Koki, A.T.; Leahy, K.M.; Masferrer, J.L.; Steele, V.E.; Kelloff, G.J.; Hill, D.L.; Seibert, K. Celecoxib inhibits N-Butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder cancers in Male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 2000, 60, 5599-5602.
36. Okajima, E.; Denda, A.; Ozono, S.; Takahama, M.; Akai, H.; Sasaki, Y.; Kitayama, W.; Wakabayashi, K.; Konishi, Y. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine. Cancer Res. 1998, 58, 3028-3031. (Pubitemid 28335083)
37. De Heer, P.; Sandel, M.H.; Guertens, G.; de Boeck, G.; Koudijs, M.M.; Nagelkerke, J.F.; Junggeburt, J.M.; de Bruijn, E.A.; van de Velde, C.J.; Kuppen, P.J. Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. Cancer Chemother. Pharmacol. 2008, 62, 811-819.
38. Keller, J.J.; Giardiello, F.M. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol. Ther. 2003, 2, 140-149.
39. Narayanan, N.K.; Nargi, D.; Horton, L.; Reddy, B.S.; Bosland, M.C.; Narayanan, B.A. Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis, preventive effects of celecoxib. Prostate 2009, 69, 133-141.
40. Ristimäki, A.; Nieminen, O.; Saukkonen, K.; Hotakainen, K.; Nordiling, S.; Haglund, C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am. J. Pathol. 2001, 158, 849-853. (Pubitemid 32221778)
41. Fernandes, J.C.; Spindola, H.; de Sousa, V.; Santos-Silva, A.; Pintado, M.E.; Malcata, F.X.; Carvalho, J.E. Anti-inflammatory activity of chitooligosaccharides in vivo. Mar. Drugs 2010, 8, 1763-1768.
42. Lee, S.H.; Senevirathne, M.; Ahn, C.B.; Kim, S.K.; Je, J.Y. Factors affecting anti-inflammatory effect of chitooligosaccharides in lipopolysaccharides-induced RAW264.7 macrophage cells. Bioorg. Med. Chem. Lett. 2009, 19, 6655-6658.
43. Baxter, A.; Dillon, M.; Taylor, K.D.A.; Robert, G.A.F. Improved method for i.r. determination of the degree of N-acetylation of chitosan. Int. J. Biol. Macromol. 1992, 14, 166-169.
44. El-kott, A.F. Flow cytometry and KI67 expression in rat's urinary bladder carcinogenesis treated with Allium sativum. Cancer Ther. 2007, 5, 185-192.
45. Estepa, V.; Ródenas, S.; Martín, M.C. Optimización de un método para la determinación de la peroxidación lipídica en suero humano. Anal. Real Acad. Nac. Farm. 2001, 67, 1-10.
46. Benzie, I.F.F.; Strain, J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": The FRAP assay. Anal. Biochem. 1996, 239, 70-76.